Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Traveling Soon? What Federal Health Plans Actually Cover
Federal employee health plans, including FEHB and related options, provide varying levels of overseas medical coverage as travel season peaks. Most plans reimburse at in‑network levels but require members to pay upfront and submit claims with translation and currency conversion. Repatriation and medical evacuation are generally excluded, prompting many to consider supplemental travel insurance. Specific plan details—APWU, Blue Cross, Compass Rose, GEHA, Aetna, etc.—outline claim procedures, network requirements, and pre‑authorization rules for emergency and non‑emergency care abroad.
KLAS Research Releases 2026 First Look Report on Abridge Ambient AI for Nursing
KLAS Research gave Abridge Ambient AI for Nursing a 94.3/100 score in its 2026 First Look report, based on early data from nine nurses across six health systems. The AI transcribes spoken observations into EHR flowsheets and links each entry...
Nelson Advisors Invited to Judge and Mentor the QSTP X Merck FemTech Accelerator 2026
Nelson Advisors has been invited to serve as a judge and mentor for the QSTP x Merck FemTech Accelerator 2026, a joint initiative between Qatar Science & Technology Park and Merck. The accelerator will select up to 30 deep‑tech FemTech startups across...
Part 1—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred of Selkirk Neurology highlights the safety profile of Vyalev (foscarbidopa/foslevodopa), a subcutaneous therapy for Parkinson's disease. He notes that injection‑site reactions such as erythema, swelling, tenderness, bruising, and induration are the most common adverse events. Aldred advises...
Q&A: Duke’s Amanda Randles, Ph.D., on the Future of Digital Twin Innovation
Dr. Amanda Randles of Duke University leads the development of HARVEY, a cardiovascular digital‑twin engine that simulates patient‑specific blood flow across the entire vasculature. The platform, originally requiring the world’s largest supercomputer for a single heartbeat, now runs in minutes...
Plug-and-Play Sensor Listens to the Developing Brain
Researchers at North Carolina State University introduced CAMEO, a low‑cost, plug‑and‑play carbon‑nanotube sensor array for human cerebral organoids. The basket‑shaped device houses 12 flexible electrodes, delivering electrophysiological recordings comparable to high‑end systems while costing a fraction of traditional microelectrode arrays....
Trump Says Federal Government Can’t Fund Medicare as Iran War Costs Mount
President Donald Trump told a White House Easter audience that the federal government cannot continue funding Medicare, Medicaid, or daycare because escalating military costs from the Iran war are draining the budget. He suggested that states should assume responsibility for...
DOJ Weighs in Favor of Pharma on 340B Dispute
The U.S. Department of Justice filed a brief backing pharmaceutical manufacturers in the ongoing 340B drug‑discount litigation. The brief argues that discounts should be calculated using the average manufacturer price rather than the lowest price, a stance that could curb...
QT Imaging Releases Next Generation of Breast Imaging Software
QT Imaging Holdings launched version 4.5.0 of its breast imaging software, introducing spatially varying deconvolution that sharpens reflection images. The update fuses speed‑of‑sound data with reflection scans, delivering richer tissue characterization and clearer visualization. It also adds optimized reconstruction for...
The Peptide Fad Lures Health Tech
Health‑tech firms are pivoting toward peptide therapeutics as the next growth engine after the blockbuster GLP‑1 weight‑loss drugs. Peptides, which include insulin and GLP‑1, are being explored for obesity, metabolic and chronic disease treatments. Industry analysts project the global peptide...
Two Neutral IVUS Trials in Complex PCI—And One Positive—Spark Debate
Three recent randomized trials compared intravascular ultrasound (IVUS) with angiography for guiding complex percutaneous coronary interventions (PCI). Only DKCRUSH VIII, which focused on true bifurcation lesions, demonstrated a 60% relative reduction in 1‑year target‑vessel failure. The European OPTIMAL and IVUS‑CHIP studies,...
General Device’s User Spotlight: Arizona — Improving Pediatric Patient Care
Phoenix Children’s Hospital upgraded its telecommunications infrastructure with General Device’s CAREpoint ED Workstation to satisfy Arizona Base Hospital certification, enabling advanced life‑support direction for incoming EMS crews. The solution integrates radio voice and video recording, real‑time data monitoring, management reporting,...
Weizmann Scientists Engineer Tobacco Plant to Produce Five Psychedelics at Once
A team from the Weizmann Institute of Science has genetically modified a tobacco plant to produce five distinct psychedelic compounds in a single host. The breakthrough could streamline drug research and reduce ecological pressure on natural sources, while raising biosecurity...
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
GENFIT reported 2025 results with cash €101.1 million (~$109 million) and revenue €65.4 million (~$70.6 million), the bulk coming from Ipsen milestones and royalties. Iqirvo® generated $208 million in full‑year sales, triggering a $20 million commercial milestone and activating an additional €30 million (~$32 million) royalty‑financing tranche. The...
Healthcare PE Outlook Shaped at HPE Miami 2026 Conference
The HPE Miami 2026 conference gathered senior healthcare private‑equity executives who outlined a bullish outlook for deal flow, highlighted evolving exit strategies, and warned of regulatory headwinds. The recap, published on JD Supra, signals how investors will shape sourcing and portfolio...
Cocrystal Pharma Shares Jump 51% After FDA Grants Fast Track to Norovirus Drug
Cocrystal Pharma (COCP) saw its shares climb 50.98% to $1.54 after the FDA granted Fast Track designation to its oral antiviral candidate CDI-988 for norovirus. The designation could accelerate development and bring the first oral therapy for the virus closer...
UK and US Lock in Pharmaceutical Deal
The United Kingdom and the United States have finalized the legal text of a landmark pharmaceutical partnership that eliminates import tariffs on U.S. medicines and certain medical technologies for at least three years. The agreement arrives amid heightened diplomatic tension,...
Mass General Brigham’s McLean Hospital Debuts HabitWorks App to Tackle Anxiety and Depression
McLean Hospital, part of Mass General Brigham, released the HabitWorks smartphone app that trains users to reinterpret ambiguous situations, a core driver of anxiety and depression. In a randomized trial of 340 adults, 77% of participants remained active after four...
Aspect Biosystems – Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
Aspect Biosystems secured a CAD $79 million (≈ $58 million USD) investment from the Government of Canada, funding a CAD $280 million (≈ $204 million USD) multi‑year project to accelerate its bioengineered cellular medicines pipeline. The funding builds on a prior CAD $200 million (≈ $146 million USD) co‑investment announced in 2024 and will expand...
Alpha Cognition Q4 2025 Earnings Show 62% Sales Surge as COO D’Angelo Drives Rollout
Alpha Cognition reported $2.8 million in Q4 2025 revenue, with ZUNVEYL sales up 62% quarter‑over‑quarter. COO Lauren D’Angelo highlighted a rapid go‑to‑market expansion across long‑term‑care facilities, while the company balances rising operating costs against a $66 million cash cushion.
ACA Premiums Spike in 2026 as Enhanced Tax Credits End, Driving Coverage Shifts
Premiums on ACA exchanges surged in 2026 after the enhanced premium tax credit expired at the end of 2025, forcing households to absorb higher costs or switch to cheaper plans. Enrollment fell by roughly 2 million, far short of earlier forecasts...
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Senators Jeanne Shaheen, Raphael Warnock, Susan Collins and John Kennedy introduced the INSULIN Act, capping private‑insurance insulin costs at $35 per month and launching a pilot for uninsured patients in ten states. The move could affect roughly 8.1 million insulin users...
AI Scribe Adoption Linked to Modest Reductions in EHR, Documentation Time: Study
A new JAMA study of more than 8,500 clinicians across five academic medical centers found that using AI‑powered scribes shaved 13 minutes off daily EHR use and 16 minutes off documentation time per provider. The efficiency boost translated into a...
Nearly 1 in 4 Pregnant Women Are Skipping Early Prenatal Care. A Veteran Nurse Explains Why that Should Worry All...
A CDC report shows first‑trimester prenatal visits dropped from 78.3% in 2021 to 75.5% in 2024, while women receiving very late or no care rose from 6.3% to 7.3%. The decline is most pronounced among Black, Native Hawaiian‑Pacific Islander, and...
Biodexa Pharma Shares Surge 69% After Partnering with Syngene to Produce MTX240
Biodexa Pharmaceuticals saw its Nasdaq‑listed shares climb 69% after revealing a partnership with Syngene International to manufacture the active pharmaceutical ingredient and dosage form of its MTX240 candidate. The deal paves the way for an IND filing and a Phase...
Scaling Security and Speed in Pharmaceutical Cold Chain Delivery at the Last Mile
Consumer expectations have shifted to hour‑level delivery, prompting big‑box retailers to add pharmaceutical cold‑chain shipments to their last‑mile services. This introduces stringent temperature, security, and compliance requirements that differ sharply from general‑merchandise fulfillment. Companies must blend rapid order processing with...
Review Finds 250 Patients Need Repeat Bone Scans
An independent review of over 1,000 DEXA bone‑density scans performed in Jersey between 2017 and 2022 uncovered reporting deficiencies. About 250 patients were identified for repeat scans, and 20 cases were judged to have received care below expected standards. Health...
Hospitals' Net Revenue Leakage Increases 25% Due to Denied Claims
Hospitals experienced a 25% jump in net‑revenue leakage in 2025, with total losses climbing to roughly $48 billion versus $38.6 billion in 2024. The surge stemmed mainly from clinical claim denials, especially for missing prior authorizations and questioned medical necessity. Medicaid accounted...
Human Factors in Safety-Critical Environments: From Operating Rooms to Urban Roads
The article argues that human factors—cognitive load, stress, fatigue, and physiological limits—shape outcomes in any safety‑critical setting, from operating rooms to urban streets. It highlights how healthcare has long used checklists, protocols and fatigue‑management programs to curb errors, and shows...
Commure Launches AI-Powered Speech-to-Cursor Dictation Tool for Clinical Workflows
Commure has unveiled Commure Dictation, an AI‑powered speech‑to‑cursor extension that turns the company’s Ambient mobile app into a wireless microphone for clinicians. The tool eliminates the need for costly, dedicated dictation hardware and enables physicians to dictate notes, messages, and referrals...
Navigation 2.0: Smarter, ROI‑Focused Healthcare Guidance
A few years ago, we were all talking about healthcare navigation as the ultimate solution for a broken system. But then the hype cooled. Why? Navigation 1.0 was built on a model that was too human-heavy, too fragmented, and too focused...
Data Ready, Timing Critical: Make Marketing Indispensable Early
Healthcare marketers already have the data, tools, and insight. The real challenge: showing it early enough to matter. Conversation with Sean Fitzpatrick on making marketing indispensable: https://t.co/IqPcreM0Mf @overit #HospitalMarketingLeaders #hcmktg
AI Tools Simplify Complex Care Data, but Risks Persist
AI-driven platforms are increasingly helping patients decode complex medical records, offering simplified visualizations and personalized insights. However, experts like Leigh Burchell of Altera Digital Health warn that many of these tools lack HIPAA compliance, exposing sensitive health data to breaches....
Trauma Surgeon Explains Compassion on Patients' Worst Day
This was one of the most powerful Health and Veritas episodes we’ve done. Trauma surgeon Dr. Selwyn Rogers on what it means to care for patients on the worst day of their lives. It was an honor to interview him. @thehowie @YaleSPH...
New HHS Hire Sparks Insightful Healthcare Policy Discussion
What a refreshingly...normal ...convo abt healthcare policy in general, & implications of new HHS hire, @1klomp, in particular, on lasted ep of the always excellent @tradeoffspod hosted by @dmgorenstein, & feat @ddiamond, reporter who (obv) Knows His Shit. https://t.co/EbUtUJMOoK
Drug Substance Maker Raises Prices Due to Energy Crisis; SpectronRX Gets $85M
BASF Pharma Solutions announced a 12% price increase on its active pharmaceutical ingredients (APIs) as soaring energy costs, driven by the ongoing Middle East conflict, strain its supply chain. The hike affects generic manufacturers and could push drug prices higher...
Longevity Tests Often Mirror Horoscopes, Not Science
What if your doctor handed you a report… and it was no more meaningful than a horoscope? That’s the uncomfortable reality we’re facing right now in longevity medicine. When clinicians use unvalidated, non-actionable tests, they are replacing evidence-based medicine with something that...
Lipocine's Postpartum Depression Drug Fails; AstraZeneca Claims Liver Cancer Win
Lipocine reported top‑line Phase 3 data for its postpartum depression candidate LPCN‑1154, revealing no statistically significant improvement over placebo and prompting a 77% plunge in its shares. The Utah‑based biotech’s safety profile was acceptable, but efficacy shortfalls undermine its commercial prospects....
Debunked Episode 25: Sutter Health’s Allina Health Acquisition Strategy, a Deep Dive on Doctronic
Sutter Health announced a cross‑border acquisition of Minnesota‑based Allina Health, marking a strategic push into health‑technology and AI. The deal gives Sutter access to Allina’s medtech engineering talent while providing Allina with the scale needed to compete against larger systems...
Q&A: Empowerment Over Information – Rethinking Patient Education
The piece argues that the flood of digital health information has outpaced patients' ability to evaluate and apply it, leaving many feeling overwhelmed rather than empowered. It highlights that clinicians often provide data without guiding patients toward trustworthy sources, and...
Convenience Wins: Consumer Health Beats Traditional Systems
Traditional healthcare is truly losing the battle of convenience. Consumer health is the real competition. Not other health systems.
HNSCC Market Is Expected to Reach to $4.5bn Across 8MM by 2034
GlobalData projects the head and neck squamous cell carcinoma (HNSCC) therapeutics market to grow from $2.0 bn in 2024 to $4.5 bn by 2034, reflecting an 8.4% compound annual growth rate. Immune checkpoint inhibitors (ICIs) dominate, accounting for 69% of 2024 sales...
How the US Christian Right and Anti-Abortion Lobbyists Are Reshaping NHS Policy
An investigation by the Good Law Project revealed that Health Secretary Wes Streeting halted the NHS puberty‑blocker trial in February 2026 after receiving a letter from Professor Jacob George, who was later removed for anti‑trans bias. The correspondence was tied...
Medicine Turns Into Low‑Cost, Check‑Box VC Model
There's so many observations here: - This is the "check a box" era of medicine - These companies do not need to raise much VC b/c the development cost is near zero - Pick the prescription, target the user, simplify the process,...
Accelerating Drug Discovery with “Paradigm Shifting” AI Model
A multi‑institution team led by Michigan State University unveiled GPS, a machine‑learning platform that predicts how a compound will alter gene expression from its chemical structure. Trained on millions of transcriptomic measurements across more than 70 cell lines, GPS screened...
AI-Powered Cohorting Is Quietly Reshaping How Real-World Evidence Gets Built
AI‑powered cohorting is redefining how real‑world evidence is generated by replacing manual SQL‑driven processes with modular, workflow‑based automation. The new approach decomposes cohort construction into discrete steps—intent interpretation, clinical concept mapping, temporal reasoning, execution, validation, and explanation—each handled by specialized...
Pfizer Halts COVID Shot Trial Because They Can’t Find Enough Test Subjects Willing to Take Another Booster Shot
Pfizer and BioNTech have halted a large U.S. clinical trial of an updated COVID‑19 booster after failing to enroll enough healthy adults aged 50‑64. The study required tens of thousands of participants, but recruitment stalled amid a sharp decline in...
Trump Is Preparing 100% Tariffs on some Drugmakers, Documents Show
President Donald Trump is preparing to announce 100% tariffs on select pharmaceutical products, according to a draft memo obtained by Endpoints News. The tariffs would apply to a limited group of drugmakers, targeting high‑priced brand‑name drugs rather than the entire...
DOJ Cracks Down On Unfair Contracts With New Lawsuit Against NewYork-Presbyterian
The U.S. Department of Justice has filed an antitrust lawsuit against NewYork‑Presbyterian Hospital, accusing it of using “all‑or‑nothing” payer contracts that force insurers to include every NYP facility in their networks. The complaint says the practice blocks lower‑cost plans, limits...
Asundexian
Bayer’s oral factor XIa inhibitor asundexian (BAY 2433334) has delivered positive Phase 3 data in the OCEANIC‑STROKE trial, positioning it as a potential first‑in‑class therapy for secondary stroke prevention. The drug aims to block pathological clot formation while minimizing the bleeding complications common...